Publicaciones en colaboración con investigadores/as de Hospital Carlos III (225)

2020

  1. Coronavirus and other airborne agents with pandemic potential

    Current Opinion in Environmental Science and Health, Vol. 17, pp. 41-48

  2. Long-acting antiretroviral therapy

    Nature Materials, Vol. 19, Núm. 8, pp. 826-827

  3. Very long-acting antivirals as chemovaccines for preventing viral infections

    AIDS Reviews

  4. Why such excess of mortality for COVID-19 in Spain?

    Therapeutic Advances in Infectious Disease

2018

  1. Hepatitis E virus, the uninvited intruder in western kitchens

    AIDS Reviews

2017

  1. Diagnosis of cutaneous anthrax in resource-poor settings in west Arsi Province, Ethiopia

    Annals of Agricultural and Environmental Medicine, Vol. 24, Núm. 4, pp. 712-715

  2. Is Ribavirin Teratogenic in Humans? No Evidence So Far

    Drug Safety

  3. Malaria and severe anemia over eight years at Gambo Rural Hospital, southern Ethiopia

    Pathogens and Global Health, Vol. 111, Núm. 4, pp. 195-199

  4. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. First Case of Zika Virus Infection in a HIV+ Patient

    AIDS reviews, Vol. 18, Núm. 2, pp. 112

  2. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

  3. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

  4. Prevalence of positive HIV, HBV, HCV and treponemal tests in blood donors in a rural hospital in southern Ethiopia

    Journal of Clinical Virology

2015

  1. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients

    Antiviral Therapy, Vol. 20, Núm. 3, pp. 329-334

  2. Long-term survival and liver-related events after pegylated interferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C

    Antiviral Therapy, Vol. 20, Núm. 1, pp. 65-72

  3. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5

  4. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2014

  1. Association of low-density lipoprotein receptor genotypes with hepatitis C viral load

    Genes and Immunity, Vol. 15, Núm. 1, pp. 16-24

  2. Causas que justifican el cambio del tratamiento antirretroviral en personas con infección por el VIH en España (años 2010-2011). Estudio SWITCH AUDIT

    Revista Espanola de Quimioterapia, Vol. 27, Núm. 2, pp. 93-97

  3. Changes in liver fibrosis in HIV/HCV-coinfected patients following different outcomes with peginterferon plus ribavirin therapy

    Journal of Viral Hepatitis, Vol. 21, Núm. 7, pp. 475-479